Keith B. Hoffman

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)